Clinical Trial Update: ZD6474 Phase IIa Dose Finding Multicentre Study [Phase 2]

View source ↗

Summary

Genzyme, a Sanofi company, sponsored a completed Phase IIa dose-finding multicentre study of ZD6474 (vandetanib) in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ZD6474 (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED